Company: NDRA
Filing Date: 2025-10-17
Form Type: PRE 14A
Source: 0001654954-25-011931
Chunk: 36

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-17
Form: PRE 14A
Chunk 36
---
|:----|:----------------------------|:---------|:--|
| 2023 |     |                                                                         | (258,341 | ) |     |                                                                                                                | 126,016 |     |                                                                                                       | - |     |                                                                                                                                | (45,526 | ) |     |                                                                                                                     | (16,886 | ) |     |                                                                                                             | - |     |                                                                                                                                                                                       | - |     |                             | (194,737 | ) |
| 2022 |     |                                                                         | (212,609 | ) |     |                                                                                                                | 124,326 |     |                                                                                                       | - |     |                                                                                                                                | (13,673 | ) |     |                                                                                                                     | (90,646 | ) |     |                                                                                                             | - |     |                                                                                                                                                                                       | - |     |                             | (192,602 | ) |

| 27 |

The amounts disclosed reflect the adjustments listed in the tables below to the amounts reported in the Summary Compensation Table for the former PEO:

| Year 
 2024 |     | Less: Value of Equity Awards Reported in the Summary Compensation Table | —        |   |     | Plus: Year End Fair Value of Outstanding and Unvested Equity Awards Granted During the Applicable Subject Year |       - |     | Plus: Vesting Date Fair Value of Equity Awards Granted and  Vested During the Applicable Subject Year | - |     | Plus/ (Less): Year-Over-Year Change in Fair Value of Outstanding and Unvested Equity Awards at Year End Granted in Prior Years |         |   |     | Plus/ (Less): Change in Value of Equity Awards Granted in Prior Years and Vested During the Applicable Subject Year | (37,133 | ) |     | Less: Fair Value at the End of the Prior Year of Equity Awards Forfeited During the Applicable Subject Year | (120,412 | ) |     | Plus: Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Fair Value or Total Compensation in the Summary Compensation Table for the Applicable Subject Year |   |     | Total Adjusted Equity Value | (157,545 | ) |
|:-----|:----|:------------------------------------------------------------------------|:---------|:--|:----|:---------------------------------------------------------------------------------------------------------------|--------:|:----|:------------------------------------------------------------------------------------------------------|:--|:----|:-------------------------------------------------------------------------------------------------------------------------------|:--------|:--|:----|:--------------------------------------------------------------------------------------------------------------------|:--------|:--|:----|: